Bristol Myers Squibb disclosed Phase 3 SUCCESSOR-2 results for mezigdomide (MeziKd) in relapsed or refractory multiple myeloma, reporting a 52% reduction in risk of disease progression or death versus the control regimen of carfilzomib plus dexamethasone (Kd). The median progression-free survival increased to 18 months in the mezigdomide arm versus 8.3 months with Kd alone. The company said the regimen produced a 80% response rate and that 27% of patients achieved no trace of disease compared with 9% in the control group. BMS also noted higher severe adverse events in the mezigdomide combination: grade 3 or 4 treatment-related adverse events were reported in 83.7% versus 56.5% in the comparator. The disclosure adds another data point to the CELMoD competitive set as BMS positions cereblon E3 ligase modulator combinations as successor therapies in a crowded myeloma market where immunotherapies and bispecifics are also moving earlier in lines of treatment.